Mycophenolate Mofetil: Effects on Cellular Immune Subsets, Infectious Complications, and Antimicrobial Activity

Overview

Journal Transpl Infect Dis

Specialties General Surgery
Infectious Diseases

Date 2009 Jun 6

PMID 19497072

Citations 63

Authors

M L Ritter

L Pirofski

Affiliations

Soon will be listed here.

Abstract

Mycophenolate mofetil (MMF) is one of the most frequently used immunosuppressive drugs in solid organ transplant recipients. MMF is an inhibitor of inosine-5'-monophosphate, and is able to preferentially inhibit B-cell and T-cell function. The immunosuppressive abilities of MMF have made it one of the most successful anti-rejection drugs in transplant patients, but patients also appear to have increased susceptibility to infections, specifically cytomegalovirus and BK virus. Despite its association with an increased risk of infection, MMF has also exhibited antimicrobial activity against pathogens including hepatitis C, Pneumocystis jirovecii, and human immunodeficiency virus. A thorough understanding of the functions of MMF on the immune system and interaction with infectious pathogens could be helpful in implementing preventative strategies against opportunistic infections in transplant patients.

Citing Articles

Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients.

Kaye A, Shah S, Johnson C, De Witt A, Thomassen A, Daniel C Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852117 PMC: 11763814. DOI: 10.3390/cimb47010002.

Polyangiitis Overlap Syndrome: Polyarteritis Nodosa with Leukocytoclastic Vasculitis Associated with Left Ventricular Thrombus and Vocal Cord Palsy: A Case Report.

Sulaiman W, Bee H, Mei L, Chun N, Wen C, Rom L Oman Med J. 2024; 39(4):e659.

PMID: 39737089 PMC: 11683395. DOI: 10.5001/omj.2024.25.

Combination of Anti-CD40 and Anti-CD40L Antibodies as Co-Stimulation Blockade in Preclinical Cardiac Xenotransplantation.

Bender M, Abicht J, Reichart B, Neumann E, Radan J, Mokelke M Biomedicines. 2024; 12(8.

PMID: 39200391 PMC: 11351779. DOI: 10.3390/biomedicines12081927.

Development of a nomogram to predict the risk of secondary failure of platelet recovery in patients with β-thalassemia major after hematopoietic stem cell transplantation: a retrospective study.

Xie Y, Yang G, Pan L, Gan Z, Huang Y, Lai Y Ther Adv Hematol. 2024; 15:20406207241245190.

PMID: 38737005 PMC: 11084996. DOI: 10.1177/20406207241245190.

Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development.

Jeong E, Hong H, Lee Y, Kim K Int J Mol Sci. 2024; 25(5).

PMID: 38473928 PMC: 11154459. DOI: 10.3390/ijms25052682.

References

Pourfarziani V, Panahi Y, Assari S, Moghani-Lankarani M, Saadat S . Changing treatment protocol from azathioprine to mycophenolate mofetil: decrease in renal dysfunction, increase in infections. Transplant Proc. 2007; 39(4):1237-40. DOI: 10.1016/j.transproceed.2007.03.006. View

Diamond M, Zachariah M, Harris E . Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology. 2002; 304(2):211-21. DOI: 10.1006/viro.2002.1685. View

Allison A, Eugui E . Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 47(2-3):85-118. DOI: 10.1016/s0162-3109(00)00188-0. View

Mehling A, Grabbe S, Voskort M, Schwarz T, Luger T, Beissert S . Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol. 2000; 165(5):2374-81. DOI: 10.4049/jimmunol.165.5.2374. View

Ahluwalia G, Cooney D, Bondoc Jr L, Currens M, Ford H, Johns D . Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2' ,3'-dideoxyguanosine. Biochem Biophys Res Commun. 1990; 171(3):1297-303. DOI: 10.1016/0006-291x(90)90827-a. View

Jonsson C, Carlsten H . Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. Int Immunopharmacol. 2003; 3(1):31-7. DOI: 10.1016/s1567-5769(02)00210-2. View

Henry S, Metselaar H, Lonsdale R, Kok A, Haagmans B, Tilanus H . Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology. 2006; 131(5):1452-62. DOI: 10.1053/j.gastro.2006.08.027. View

Heredia A, Margolis D, Oldach D, Hazen R, Le N, Redfield R . Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J Acquir Immune Defic Syndr. 2000; 22(4):406-7. DOI: 10.1097/00126334-199912010-00013. View

Eugui E, Almquist S, Muller C, Allison A . Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol. 1991; 33(2):161-73. DOI: 10.1111/j.1365-3083.1991.tb03746.x. View

10.

Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R . Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr. 1999; 21(5):362-70. View

11.

Kimball J, Pescovitz M, Book B, Norman D . Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation. 1995; 60(12):1379-83. DOI: 10.1097/00007890-199560120-00001. View

12.

Hardwick L, Savatta S, Book B, Milgrom M, McQueen J, Anderson M . Effect of mycophenolate mofetil on the Anti-CMV serologic response after renal transplantation. Transplant Proc. 2001; 33(1-2):1865-6. DOI: 10.1016/s0041-1345(00)02727-5. View

13.

Jorge S, Guerra J, Santana A, Mil-Homens C, Prata M . Mycophenolate mofetil: ten years' experience of a renal transplant unit. Transplant Proc. 2008; 40(3):700-4. DOI: 10.1016/j.transproceed.2008.02.028. View

14.

Pourmand G, Salem S, Mehrsai A, Taherimahmoudi M, Ebrahimi R, Pourmand M . Infectious complications after kidney transplantation: a single-center experience. Transpl Infect Dis. 2007; 9(4):302-9. DOI: 10.1111/j.1399-3062.2007.00229.x. View

15.

Lauzurica R, Bayes B, Frias C, Fontsere N, Hernandez A, Matas L . Disseminated varicella infection in adult renal allograft recipients: role of mycophenolate mofetil. Transplant Proc. 2003; 35(5):1758-9. DOI: 10.1016/s0041-1345(03)00684-5. View

16.

Sankatsing S, Jurriaans S, Swieten P, van Leth F, Cornelissen M, Miedema F . Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS. 2004; 18(14):1925-31. DOI: 10.1097/00002030-200409240-00008. View

17.

Meier-Kriesche H, Friedman G, Jacobs M, Mulgaonkar S, Vaghela M, Kaplan B . Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols. Transplantation. 1999; 68(10):1496-502. DOI: 10.1097/00007890-199911270-00012. View

18.

Zmonarski S, Boratynska M, Madziarska K, Klinger M, Kusztel M, Patrzalek D . Mycophenolate mofetil severely depresses antibody response to CMV infection in early posttransplant period. Transplant Proc. 2003; 35(6):2205-6. DOI: 10.1016/s0041-1345(03)00764-4. View

19.

Neyts J, Meerbach A, McKenna P, De Clercq E . Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res. 1996; 30(2-3):125-32. DOI: 10.1016/0166-3542(96)89697-5. View

20.

Bao H, Liu Z, Xie H, Hu W, Zhang H, Li L . Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008; 19(10):2001-10. PMC: 2551567. DOI: 10.1681/ASN.2007121272. View